Navigation Links
A new agent for the treatment of patients with myelodysplastic syndrome; and more
Date:2/11/2008

A new agent for the treatment of patients with myelodysplastic syndrome

In a paper published this week in PLoS Medicine, Azra Raza and colleagues (University of Massachusetts) use gene expression profiling to identify a molecular signature that predicts response to lenalidomide in patients without chromosome 5q deletions. This suggests that these patients have a defect in erythroid differentiation.

In a related review article, Jerry Radich (Fred Hutchinson Cancer Research Center, Seattle, USA) reviews key research on the biology underlying treatment response in myelodysplasia, including Raza and colleagues' new study.

Citation: Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, et al. (2008) An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 5(2): e35.

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE

VERSIONS OF YOUR REPORT: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050035

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-05-02-raza.pdf

CONTACT:

Azra Raza
University of Massachusetts
Division of Hematology Oncology
Worcester, MA 01605
United States of America
araza@aptiumoncology.com


Related PLoS Medicine perspective article:

Citation: Radich J (2008) Solving the mystery of myelodysplasia. PLoS Med 5(2): e40

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE

VERSIONS OF YOUR REPORT: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050040

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-05-02-radich.pdf

CONTACT:

Jerry Radich
Fred Hutchinson Cancer Research Center
Clinical Research Division
Seattle, Washington
United States of America
+1 206-667-4118
jradich@fhcrc.org


FROM THE PLoS MEDICINE MAGAZINE SECTION:

Salivating for knowledge: potential pharmacological agents in tick saliva

Joppe Hovius (University of Amsterdam) and colleagues review anticoagulant and immunosuppressive proteins present in tick saliva, and discuss how immunologically targeting such molecules could prevent transmission of tick-borne pathogens.

Citation: Hovius JWR, Levi M, Fikrig E (2008) Salivating for knowledge: Potential pharmacological agents in tick saliva. PLoS Med 5(2): e43.

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE

VERSIONS OF YOUR REPORT: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050043

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-05-02-hovius.pdf

CONTACT:

Joppe Hovius
University of Amsterdam, AMC
Center for Experimental and Molecular Medicine
Meibergdreef 9
Amsterdam, Noord-Holland 1105 AZ
Netherlands
+31205666034
+31206977192 (fax)
j.w.hovius@amc.uva.nl


'/>"/>

Contact: Josh Eveleth
jeveleth@plos.org
415-624-1234
Public Library of Science
Source:Eurekalert

Related medicine news :

1. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
2. ABR-Affinity BioReagents Participates in the 2008 Fisher Scientific Supplier Expo in San Antonio, Texas
3. LiquidAgents Healthcare, LLC Awarded Accreditation from the Joint Commission
4. Insurance Agents Call for State Senate to Improve Californias Health Care Reform Compromise
5. Allergic reactions to gadolinium-based contrast agents are rare, study finds
6. Make 2008 the Year to Find an Insurance Agent Thats Right for You
7. Agent orange chemical, dioxin, attacks the mitochondria to cause cancer, says Penn research team
8. Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
9. Germ-Fighting Inhaler Could Fend Off Bioterror Agents
10. National Patient Advocate Foundation (NPAF) Statement Regarding New FDA Label on Erythropoietin Stimulating Agents (ESAs)
11. Benepath Launches Exclusive Marketing Service for Health Insurance Agents and Agencies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused ... in efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, ... is honored to team up with Upstage Lung Cancer in order to make major ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
(Date:12/8/2016)... ... , ... STAT courier is pleased to announce that due to customer demand, ... expanding their presence in Dallas. One of the most exciting parts for STAT is ... the Dallas and Forth Worth market. STAT takes pride in treating their employees with ...
(Date:12/8/2016)... ... 08, 2016 , ... Vida Health, the digital health platform that ... Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and returning investor ... more consumers who are managing chronic conditions or simply want to improve ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
(Date:12/8/2016)... A Small Business Innovative Research (SBIR) grant ... (NIH) to Phoenix -based NeuroEM Therapeutics, ... grant will seek to determine an optimal set of ... waves to treat Alzheimer,s Disease. The grant will also ... treat other neurologic disorders such as Parkinson,s Disease and ...
(Date:12/8/2016)... New York , December 8, 2016 ... global Diabetes Injection Pens Market is expected to ... compared to US$4.9 bn in 2015. Between the forecast years ... rise at a CAGR of 7.9%. The leading players operating ... A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., and ...
Breaking Medicine Technology: